Preoperative Cell-free DNA Concentration in Plasma As a Diagnostic and Prognostic Biomarker of Clear Cell Renal Cell Carcinoma

Overview

Journal Contemp Oncol (Pozn)

Publisher Termedia

Specialty Oncology

Date 2024 Feb 26

PMID 38405214

Authors

Tomasz Milecki

Katarzyna Kluzek

Natalia Pstrag

Andrzej Antczak

Wojciech A Cieslikowski

Mateusz Wichtowski

Lukasz Kuncman

Zbigniew Kwias

Joanna Wesoly

Affiliations

Soon will be listed here.

Abstract

Introduction: Assessment of renal tumour masses is based on conventional imaging studies (computer tomography or magnetic resonance), which does not allow characterisation of the histopathological type. Moreover, the prediction of prognosis in localised and metastatic renal cell carcinoma requires improvement as well. Analysis of circulating free DNA (cfDNA) in blood is one of the variants of liquid biopsy that may improve diagnostics and prognosis issues of patients with renal tumour masses suspected to be renal cell carcinoma. The aim of the study was to assess the diagnostic and prognostic role of preoperative cfDNA concentration in the plasma samples of clear cell renal cell carcinoma (ccRCC) patients.

Material And Methods: The preoperative plasma cfDNA concentration was assessed in ccRCC patients ( = 46) and healthy individuals (control group) ( = 17). The circulating free DNA concentration was reflected by the 90 bp DNA fragments determined by real-time polymerase chain reaction.

Results: The median cfDNA concentration was significantly higher in ccRCC patients ( = 46) compared to the control g roup ( = 17) (2588 ±2554 copies/ml vs. 960 ±490 copies/ml, < 0.01). In multivariate analysis, the preoperative plasma cfDNA concentration was the significant factor increasing the probability of ccRCC detection (OR: 1.003; 95% CI: 1.001-1.005). The median cfDNA concentration depended on the stage of ccRCC; it was higher in metastatic ccRCC patients ( = 11) compared to non-metastatic ccRCC patients ( = 35) (3619 ±4059 copies/ml vs. 2473 ±1378 copies/ml, < 0.03). Kaplan-Meier survival analysis demon-strated that patients with high cfDNA values (above 2913 copies/ml) had significantly worse cancer-specific survival (HR: 4.5; 95% CI: 1.3-16.9, log-rank Mantel-Cox test = 0.015).

Conclusions: Preoperative plasma cfDNA concentration has diagnostic and prognostic potential in ccRCC pa-tients.

References

Tug S, Helmig S, Deichmann E, Schmeier-Jurchott A, Wagner E, Zimmermann T . Exercise-induced increases in cell free DNA in human plasma originate predominantly from cells of the haematopoietic lineage. Exerc Immunol Rev. 2015; 21:164-73. View

Chan A, Chiu R, Lo Y . Cell-free nucleic acids in plasma, serum and urine: a new tool in molecular diagnosis. Ann Clin Biochem. 2003; 40(Pt 2):122-30. DOI: 10.1258/000456303763046030. View

Jung M, Klotzek S, Lewandowski M, Fleischhacker M, Jung K . Changes in concentration of DNA in serum and plasma during storage of blood samples. Clin Chem. 2003; 49(6 Pt 1):1028-9. DOI: 10.1373/49.6.1028. View

Oxnard G, Thress K, Alden R, Lawrance R, Paweletz C, Cantarini M . Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016; 34(28):3375-82. PMC: 5035123. DOI: 10.1200/JCO.2016.66.7162. View

Patel H, Johnson M, Pierorazio P, Sozio S, Sharma R, Iyoha E . Diagnostic Accuracy and Risks of Biopsy in the Diagnosis of a Renal Mass Suspicious for Localized Renal Cell Carcinoma: Systematic Review of the Literature. J Urol. 2016; 195(5):1340-1347. PMC: 5609078. DOI: 10.1016/j.juro.2015.11.029. View

OConnell G, Petrone A, Tennant C, Lucke-Wold N, Kabbani Y, Tarabishy A . Circulating extracellular DNA levels are acutely elevated in ischaemic stroke and associated with innate immune system activation. Brain Inj. 2017; 31(10):1369-1375. DOI: 10.1080/02699052.2017.1312018. View

Lander E, Linton L, Birren B, Nusbaum C, Zody M, Baldwin J . Initial sequencing and analysis of the human genome. Nature. 2001; 409(6822):860-921. DOI: 10.1038/35057062. View

Perego R, Corizzato M, Brambilla P, Ferrero S, Bianchi C, Fasoli E . Concentration and microsatellite status of plasma DNA for monitoring patients with renal carcinoma. Eur J Cancer. 2008; 44(7):1039-47. DOI: 10.1016/j.ejca.2008.03.008. View

Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N . Drug resistance in cancer: an overview. Cancers (Basel). 2014; 6(3):1769-92. PMC: 4190567. DOI: 10.3390/cancers6031769. View

10.

de Martino M, Klatte T, Haitel A, Marberger M . Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker. Cancer. 2011; 118(1):82-90. DOI: 10.1002/cncr.26254. View

11.

Eggener S, Yossepowitch O, Pettus J, Snyder M, Motzer R, Russo P . Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol. 2006; 24(19):3101-6. DOI: 10.1200/JCO.2005.04.8280. View

12.

Markus H, Contente-Cuomo T, Farooq M, Liang W, Borad M, Sivakumar S . Evaluation of pre-analytical factors affecting plasma DNA analysis. Sci Rep. 2018; 8(1):7375. PMC: 5943304. DOI: 10.1038/s41598-018-25810-0. View

13.

Devonshire A, Whale A, Gutteridge A, Jones G, Cowen S, Foy C . Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal Bioanal Chem. 2014; 406(26):6499-512. PMC: 4182654. DOI: 10.1007/s00216-014-7835-3. View

14.

Salvi S, Gurioli G, De Giorgi U, Conteduca V, Tedaldi G, Calistri D . Cell-free DNA as a diagnostic marker for cancer: current insights. Onco Targets Ther. 2016; 9:6549-6559. PMC: 5087772. DOI: 10.2147/OTT.S100901. View

15.

Gong J, Maia M, Dizman N, Govindarajan A, Pal S . Metastasis in renal cell carcinoma: Biology and implications for therapy. Asian J Urol. 2017; 3(4):286-292. PMC: 5730828. DOI: 10.1016/j.ajur.2016.08.006. View

16.

Dawson S, Tsui D, Murtaza M, Biggs H, Rueda O, Chin S . Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013; 368(13):1199-209. DOI: 10.1056/NEJMoa1213261. View

17.

Di Meo A, Bartlett J, Cheng Y, Pasic M, Yousef G . Liquid biopsy: a step forward towards precision medicine in urologic malignancies. Mol Cancer. 2017; 16(1):80. PMC: 5391592. DOI: 10.1186/s12943-017-0644-5. View

18.

Schwarzenbach H, Hoon D, Pantel K . Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011; 11(6):426-37. DOI: 10.1038/nrc3066. View

19.

Tan G, Chu C, Gui X, Li J, Chen Q . The prognostic value of circulating cell-free DNA in breast cancer: A meta-analysis. Medicine (Baltimore). 2018; 97(13):e0197. PMC: 5895387. DOI: 10.1097/MD.0000000000010197. View

20.

Graham J, Dudani S, Heng D . Prognostication in Kidney Cancer: Recent Advances and Future Directions. J Clin Oncol. 2018; :JCO2018790147. DOI: 10.1200/JCO.2018.79.0147. View